Early phytocannabinoid chemistry to endocannabinoids and beyond

Nature Reviews Neuroscience

Volumn 15, Issue 11, 2014, Pages 757-764

  Mechoulam, Raphael ^a   Hanuš, Lumír O ^a   Pertwee, Roger ^b   Howlett, Allyn C ^c  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABIS; ENDOCANNABINOID; LIGAND; RIMONABANT; CANNABINOID 1 RECEPTOR; PLANT EXTRACT;

BEHAVIOR THERAPY; BIOSYNTHESIS; BRAIN DISEASE; BRAIN FUNCTION; CANNABIS USE; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG IDENTIFICATION; DRUG INDUSTRY; HISTORY; HUMAN; MOLECULAR BIOLOGY; NEUROMODULATION; NEUROPHARMACOLOGY; NONHUMAN; PHYTOCANNABINOID CHEMISTRY; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; ANIMAL; CENTRAL NERVOUS SYSTEM; DRUG EFFECTS; METABOLISM;

ANIMALS; CENTRAL NERVOUS SYSTEM; ENDOCANNABINOIDS; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; NEUROPHARMACOLOGY; PLANT EXTRACTS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 84908133711     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/nrn3811     Document Type: Review

References (119)

1. Mechoulam, R. in Cannabinoids as Therapeutic Agents, (ed. Mechoulam, R.), 1-19 (CRC Press Inc., 1986).
2. O'Shaugnessy, W. B. in The Bengal Dispensatory and Pharmacopoeia, 579 (Bishop's College Press, 1841).
3. Adams, R. Marihuana. Harvey Lectures 37, 168-197 (1941-1942).
4. Todd, A. R. Hashis h. Experientia 2, 55-60 (1946).
5. Loewe, S. Cannabiswirkstoffe und Pharmacologie der Cannabinole. Arch. Exp. Pathol. Pharmacol. 211, 175-193 (1950).
6. Gaoni, Y. & Mechoulam, R. Isolation, structure and partial synthesis of an active constituent of hashish. J. Amer. Chem. Soc. 86, 1646-1647 (1964).
7. Mechoulam, R., McCallum, N. K. & Burstein, S. Recent advances in the chemistry and biochemistry of cannabis. Chem. Rev. 76, 75-112 (1976).
8. Agurell, S. et al. Pharmacokinetics and metabolism of -1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol. Rev. 38, 21-43 (1986).
9. Pertwee, R. G. The ring test: a quantitative method for assessing the 'cataleptic' effect of cannabis in mice. Br. J. Pharmacol. 46, 753-763 (1972).
10. Pertwee, R. G. Cannabinoid pharmacology: the first 66 years. Br. J. Pharmacol. 147, S163-S171 (2006).
11. Pertwee, R. G. The central neuropharmacology of psychotropic cannabinoids. Pharmacol. Ther. 36, 189-261 (1988).
12. Pertwee, R. G. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br. J. Pharmacol. 156, 397-411 (2009).
13. Mechoulam, R. et al. Stereochemical requirements for cannabinoid activity. J. Med. Chem. 23, 1068-1072 (1980).
14. Mechoulam, R. et al. Enantiomeric cannabinoids: stereospecificity of psychotropic activity. Experientia 44, 762-764 (1988).
15. Dewey, W. L. Cannabinoid pharmacology. Pharmacol. Rev. 38, 151-178 (1986).
16. Hollister, L. E. Health aspects of cannabis. Pharmacol. Rev. 38, 1-20 (1986).
17. Klee, W. A., Sharma, S. K. & Nirenberg, M. Opiate receptors as regulators of adenylate cyclase. Life Sci. 16, 1869-1874 (1975).
18. Nathanson, N. M., Klein, W. L. & Nirenberg, M. Regulation of adenylate cyclase activity mediated by muscarin ic acetylcholine receptors. Proc. Natl Acad. Sci. USA 75, 1788-1791 (1978).
19. Sabol, S. L. & Nirenberg, M. Regulation of adenylate cyclase of neuroblastoma x glioma hybrid cells by -Adrenergic receptor s. I. Inhibition of adenylate cyclase mediated by ? receptors. J. Biol. Chem. 254, 1913-1920 (1979).
20. Howlett, A. C. & Fleming, R. M. Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol. Pharmacol. 26, 532-538 (1984).
21. Howlett, A. C. Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds. Life Sci. 35, 1803-1810 (1984).
22. Howlett, A. C. Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Mol. Pharmacol. 27, 429-436 (1985).
23. Howlett, A. C., Qualy, J. M. & Khachatrian, L. L. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol. Pharmacol. 29, 307-313 (1986).
24. Howlett, A. C., Cham pion, T. M., Wilken, G. H. & Mechoulam, R. Stereochemical effects of 11-OH-? 8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor. Neuropharmacology 29, 161-165 (1990 ).
25. Melvin, L. S. et al. Structure-Activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs. Mol. Pharmacol. 44, 1008-1015 (1993).
26. Melvin, L. S., Milne, G. M., Johnson, M. R., Wilken, G. H. & Howlett, A. C. Structure-Activity relationships defining the ACD-tricyclic cannabinoids: cannabinoid receptor binding and analgesic activity. Drug Des. Dis cov. 13, 155-166 (1995).
27. Devane, W. A., Dysarz F. A. 3rd, Johnson M. R., Melvin L. S. & Howlett A. C. Determination and characterization of a cannabinoid receptor in rat brain. Mol.Pharmacol. 34, 605-613 (1988).
28. Gerard, C., Mollereau, C., Vassart, G. & Parmentier, M. Nucleotide sequence of a human cannabinoid receptor cDNA. Nucleic Acids Res. 18, 7142 (1990).
29. Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C. & Bonner, T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564 (1990).
30. Devane, W. A. et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949 (1992).
31. Munro, S., Thomas, K. L. & Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65 (1993).
32. Mechoulam, R. et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83-90 (1995).
33. Pertwee, R. G. et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol. Rev. 62, 588-631 (2010).
34. Pamplona, F. A. et al. Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor. Proc. Natl Acad. Sci. USA 109, 21134-21139 (2012).
35. Bauer, M. et al. Identification and quantification of a new family of peptide endocannabinoids (pepcans) showing negative allosteric modulation at CB1 receptors. J. Biol. Chem. 287, 36944-36967 (2012).
36. Heimann, A. S. et al. Hemopressin is an inverse agonist of CB1 cannabinoid receptors. Proc. Natl Acad. Sci. USA 104, 20588-20593 (2007).
37. Huffm an, J. W. et al. Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J. Med. Chem. 39, 3875-3877 (1996).
38. Hanu͉ , L. et al. HU-308: A specific agonist for CB2, a peripheral cannabinoid receptor. Proc. Natl Acad. Sci. USA 96, 14228-14233 (1999).
39. Anand, P., Whiteside, G., Fowler, C. J. & Hohmann, A. G. Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res. Rev. 60, 255-266 (2009).
40. Fernandez-Ruiz, J., Pazos, M. R., Garcia-Arencibia, M., Sagredo, O. & Ramos, J. A. Role of CB2 receptors in neuroprotective effects of cannabinoids. Mol. Cell. Endocrinol. 286, S91-S96 (2008).
41. Marriott, K. S. & Huffman, J. W. Recent advances in the development of selective ligands for the cannabinoid CB2 receptor. Curr. Top. Med. Chem. 8, 187-204 (2008).
42. Pacher, P.,Mechoulam, R. Is lipid signaling through cannabinoid 2 receptors part of a protective system? Progr. Lipid Res. 50, 193-211, 2011).
43. Horvth, B. et al. A new cann abinoid 2 receptor agonist HU-910 attenuates oxidative stress, inflammation, and cell death associated with hepatic ischemia/reperfusion injury. Br. J. Pharmacol. 165, 2462-2478 (2012).
44. Di Marzo, V., De Petrocellis, L. & Bisogno, T. in Cannabinoids. Handbook of Expermimental Pharmacology (ed. Pertwee, R. G.) 168, 147-185 (Springer, 2005).
45. Wilson, R. I. & Nicoll R. A. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410, 588-592 (2001).
46. Vaughan, C. W. & Christie, M. J. in Cannabinoids. Handbook of Expermimental Pharmacology (ed. Pertwee, R. G.) 168, 367-383 (Springer, 2005).
47. Ohno-Shosaku, T., Tanimura, A., Hashimotodani, Y. & Kano, M. Endocannabinoids and retrograde modulation of synaptic transmission. Neuroscientist 18, 119-132 (2012).
48. Alger, B. E. Endocannabinoids at the synapse a decade after the dies mirabilis: what we still do not know. J. Physiol. 590, 2203-2212 (2012).
49. Gregg, L. C. et al. Activation of type 5 metabotropic glutamate receptors and diacylglycerol lipase-? initiates 2-Arachidonoylglycerol formation and endocannabinoid-mediated analgesia. J. Neurosci. 32, 9457-9468 (2012).
50. Rinaldi-Carmona, M. et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350, 240-244 (1994).
51. Rinaldi-Carmona, M. et al. Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. Life Sci. 58, 1239-1247 (1996).
52. Mathews, W. B. et al. Biodistribution of [18F] SR144385 and [18F] SR147963: selective radioligands for positron emission tomographic studies of brain cannabinoid receptors. Nucl. Med. Biol. 27, 757-762 (2000).
53. Bouaboula, M. et al. Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells. J. Biol. Chem. 270, 13973-13980 (1995).
54. Bouaboula, M. et al. Activation of mitogen-Activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem. J. 312, 637-641 (1995).
55. Bouaboula, M. et al. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-Ac tivated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J. Biol. Chem. 272, 22330-22339 (1997).
56. Compton, D. R., Aceto, M. D., Lowe, J. & Martin, B. R. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of ? 9-tetrahydrocannabinol-induced responses and apparent agonis t activity. J. Pharmacol. Exp. Ther. 277, 586-594 (1996).
57. Gueudet, C., Santucci, V., Rinaldi-Carmona, M., Soubrie, P. & Le Fur, G. The CB1 cannabinoid receptor antagonist SR141716A affects A9 dopamine neuronal activity in the rat. Neuroreport 6, 1421-1425 (1995).
58. Perio, A. et al. Central mediation of the cannabinoid cue: activity of a selective CB1 antagonist, SR141716A. Behav. Pharmacol. 7, 65-71 (1996).
59. Aceto, M. D., Scates, S. M., Lowe, J. A. & Martin, B. R. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR141716A. Eur. J.Pharmacol. 282, R1-R2 (1995).
60. Tsou, K., Patrick, S. L. & Walker, J. M. Physical withdrawal in rats tolerant to ? 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur. J. Pharmacol. 280, R13-R15 (1995).
61. Felder, C. C. et al. LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J. Pharmacol. Exp. Th er. 284, 291-297 (1998).
62. Meschler, J. P., Kraichely, D. M., Wilken, G. H. & Howlett, A. C. Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB1 cannabinoid receptor. Biochem. Pharmacol. 60, 1315-1323 (2000).
63. Cosenza M.,et al. Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist/inverse agonist AM281 Synapse, 38, 477-482, 2000).
64. Lan, R. et al. Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand. AAPS Pharm. Sci. 1, E4 (1999).
65. Pertwee, R. et al. AM630, a competitive cannabinoid receptor antagonist. Life Sci. 56, 1949-1955 (1995).
66. Rinaldi-Carmona, M. et al. SR144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284, 644-650 (1998).
67. Cascio, M. G. et al. In vitro and in vivo pharmacological characterization of two novel selective cannabinoid CB2 receptor inverse agonists. Pharmacol. Res. 61, 349-354 (2010).
68. Miller, A. M. & Stella, N. CB2 receptor-mediated migration of immune cells: it can go either way. Br. J. Pharmacol. 153, 299-308 (2008).
69. Fernandez-Ruiz, J. et al. Cannabin oid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol. Sci. 28, 39-45 (2007).
70. Wright, K. L., Duncan, M. & Sharkey, K. A. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br. J. Pharmacol. 153, 263-270 (2008).
71. Lunn, C. A. et al.Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists. Br. J. Pharmacol. 153, 226-239 (2008).
72. Scheen, A. J. et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368, 1660-1672 (2006).
73. Nissen, S. E. et al. Effect of rimonabant on progression of atherosclerosis in patients with abdomina l obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 299, 1547-1560 (2008).
74. Van Gaal, L. F., Rissanen, A. M., Scheen, A. J., Ziegler, O. & Rossner, S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365, 1389-1397 (2005).
75. Moreira, F. A., Grieb, M. & Lutz, B. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract. Res. Clin. Endocrinol. Metab. 23, 133-144 (2009).
76. Nathan, P. J., O'Neill, B. V., Napolitano, A. & Bullmore, E. T. Neuropsychiatric adverse effects of centrally acting antiobesity drugs. CNS Neurosci. Ther. 17, 490-505 (2011).
77. Di Marzo, V. & Despres, J. P. CB1 antagonists for obesity-what lessons have we learned from rimonabant? Nature Rev. Endocrinol. 5, 633-638 (2009).
78. Kiril ly, E., Gonda, X. & Bagdy, G. CB1 receptor antagonists: new discoveries leading to new perspectives. Acta Physiol. 205, 41-60 (2012).
79. Tam, J. et al. Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell. Metab. 16, 167-179 (2012).
80. Lazary, J., Juhasz, G., Hunyady, L. & Bagdy, G. Personalized medicine can pave the way for the safe use of CB1 receptor antagonists. Trends Pharmacol. Sci. 32, 270-280 (2011).
81. Blankman, J. L. & Cravatt, B. F. Chemical probes of endocannabinoid metabolism. Pharmacol. Rev. 65, 849-871 (2013).
82. Pertwee, R. G. Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications. Proc. Nutr. Soc. 73, 96-105 (2014).
83. Pertwee, R. G. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J. 7, E625-E654 (2005).
84. Pacher, P. & Kunos, G. Modulating the endocannabinoid system in human health and disease-successes and failures. FEBS J. 280, 1918-1943 (2013).
85. Pertwee, R. G. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: ?9-tetrahydrocannabinol, cannabidiol and ?9-tetrahydrocannabivarin. Br. J. Pharmacol. 153, 199-215 (2008).
86. Pertwee, R. G. Receptors and chann els targeted by synthetic cannabinoid receptor agonists and antagonists. Curr. Med. Chem. 17, 1360-1381 (2010).
87. Pertwee, R. G. & Cascio, M. G. in Handbook of Cannabis (ed. Pertwee, R. G.) 115-136 (Oxford University Press, 2014).
88. Pertwee, R. G. Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem. 6, 635-664 (1999).
89. McHugh, D., Page, J., Dunn, E. & Bradshaw, H. B. ?9-Tetrahydrocannabinol and N-Arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells. Br. J. Pharmacol. 165, 2414-2424 (2012).
90. De Petrocellis, L. et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br. J. Pharmacol. 163, 1479-1494 (2011).
91. Di Marzo, V. A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British scientists. Trends Pharmacol. Sci. 27, 134-140 (2006).
92. Howlett, A. C., Blume, L. C. & Dalton, G. D. CB1 cannabinoid receptors and their associated proteins. Curr. Med. Chem. 17, 1382-1393 (2010).
93. Smith, T. H., Sim-Selley, L. J. & Selley, D. E. Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery? Br. J. Pharmacol. 160, 454-466 (2010).
94. Tan, B. et al. Targeted lipidomics: discovery of new fatty acyl amides. AAPS J. 8, E461-E465 (2006).
95. Tan, B. et al. Identification of endogenous acyl amino acids based on a targeted lipidomics approach. J. Lipid Res. 51, 112-119 (2010).
96. Milman, G. et al. N-Arachidonoyl l-serine, a novel endocannabinoid-like brain constituent with vasodilatory properties. Proc. Natl Acad. Sci. USA 103, 2428-2433 (2006).
97. Cohen-Yeshurun, A. et al. N-Arachidonoyl-l-serine is neuroprotective after traumatic brain injury by reducing apoptosis. J. Cereb. Blood Flow Metab. 31, 1768-1777 (2011).
98. Cohen-Yeshurun, A. et al. N-Arachidonoyl-l-serine (AraS) possesses pro-neurogenic properties in vitro and in vivo following traumatic brain injury. J. Cereb. Blood Flow Metab. 33, 1242-1250 (2013).
99. Pucci, M. et al. Epigenetic control of skin differentiation genes by phytocannabinoids. Br. J. Pharmacol. 170, 581-591 (2013).
100. Pasquariello, N., Oddi, S., Malaponti, M. & Maccarrone, M. Regulation of gene transcription and keratinocyte differentiation by anandamide. Vitam. Horm. 81, 441-467 (2009).
101. Leweke, F. M. et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl. Psychiatry 2, e94 (2012).
102. Porter, B. E. & Jacobson, C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav. 29, 574-577 (2013).
103. Cunha, J. M. et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacol. 21, 175-185 (1980).
104. Wood, T. B., Spivey, W. T. N. & Easterfield, T. H. Cannabinol. Part I. J. Chem. Soc. 75, 20-36 (1899).
105. Cahn, R. S. Cannabis indica resin, Part, III The constitution of Cannabinol. J. Chem. Soc. 1342-1353 (1932).
106. Mechoulam R.,Shvo Y. The structure of cannabidiol Tetrahedron 19, 2073-2078, 1963).
107. Sugiura, T. et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215, 89-97 (1995).
108. Cravatt, B. F. et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty-Acid amides. Nature 384, 83-87 (1996).
109. Zygmunt, P. M. et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400, 452-457 (1999).
110. Smart, D. et al. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol. 129, 227-230 (2000).
111. Piomelli, D. A fatty gut feeling. Trends Endocrinol. Metab. 24, 332-341 (2013).
112. Bandiera, T., Ponzano, S. & Piomelli, D. Advances in the discovery of N-Acylethanolamine acid amidase inhibitors. Pharmacol. Res. 86C, 11-17 (2014).
113. Schlosburg, J. E. e t al. Prolonged monoacylglycerol lipase blockade causes equivalent cannabinoid receptor type 1 receptor-mediated adaptations in fatty acid amide hydrolase wild-type and knockout mice. J. Pharmacol. Exp. Ther. 350, 196-204 (2014).
114. Galve-Roperh, I. et al. Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation. Prog. Lipid Res. 52, 633-650 (2013).
115. Katona, I. & Freund, T. F. Multiple functions of endocannabinoid signaling in the brain. Annu. Rev. Neurosci. 35, 529-558 (2012).
116. Piomelli, D. & Sasso, O. Peripheral gating of pain signals by endogenous lipid mediators. Nature Neurosci. 17, 164-174 (2014).
117. Syed, Y. Y., McKeage, K. & Scott, L. J. -9-tetrahydrocannabinol/cannabidiol (Sativex): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis. Drugs 74, 563-578 (2014).
118. Roitman, P., Mechoulam, R., Cooper-Kazaz, R. & Shalev, A. Preliminary, open-label, pilot st udy of add-on oral ?(9)-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clin. Drug Investig. 34, 587-591 (2014).
119. Bisogno, T. et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J. Cell Biol. 163, 463-468 (2003).